FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029763038> ?p ?o ?g. }

• W3029763038 abstract "e21503 Background: The use of immune checkpoint inhibitors (ICIs) drastically transformed the treatment of lung cancer. However, a variety of response rates have been observed in patients due to intrinsic or acquired resistances. STK11 mutated patients represent a subgroup of lung cancer patients with diminished outcomes when given ICIs, with some of these patients developing hyperprogressive disease (HPD). Methods: In this study, a retrospective cohort of 384 lung cancer patients previously treated with ICIs was identified from the City of Hope Thoracic Registry (THOR) with a cutoff date of November 11, 2018. Next-generational sequencing (NGS) was performed on 246 patients. 24 of these patients were harboring an alteration in STK11. Data was collected on these patients until December 31, 2019. HPD was exclusively defined by time-to-treatment failure (TTF) < 2 months (TTF is defined as the time from the start of treatment with ICI to ICI discontinuation for any reason, including progression, patient preference, toxicity, or death). Overall survival (OS) and progression free survival (PFS) was started from the initiation of ICI therapy. OS and PFS was calculated between 2 groups (HPD vs non-HPD) using the Mantel-Cox Log-rank test. Results: Almost half (11/13; 45.8%) of the patients with STK11 developed HPD. There was a significant difference between HPD and non-HPD patients in median OS (2 vs 23 months; p = 0.0013) and median PFS (1 v 9 months; p < 0.0001). The median age was 66 (range, 41-90) years old with the majority of patients female (14/24; 58.3%). Most of the patients are deceased (16/24; 66.7%). 91.7% of STK11 patients histologically were adenocarcinoma and 91.7% were smokers with a median pack year history of 40 (range, 4-90). All of the patients had metastatic disease presenting with stage IV disease (21/24; 87.5%). ICI therapies used were pembrolizumab (11/24; 45.8%), Atezolizumab (8/24; 33.3%), nivolumab (4/24; 16.7%), and durvalumab (1/24; 4.2%). PD-L1 expression varied: negative (8/24; 33.3%), 1%- < 50% (7/24; 29.2%), ≥50% (4/24; 16.7%), and not reported (5/24; 20.8%). The most commonly occurring co-mutations were found in TP53 (14/24; 58.3%), KRAS (12/24; 50.0%), SMARCA4 (9/24; 37.5%), PRKDC (8/24; 33.3%) and LRP1B (8/24; 33.3%). Three patients had a pathological co-mutation that is targetable (1 ALK rearrangement, 1 EGFR exon 19 deletion, and 1 RET fusion). Conclusions: STK11 patients who developed HPD had worse OS and PFS compared to STK11 patients without HPD. These results are preliminary and additional analysis is needed to compare differences between various cohorts." @default.
• W3029763038 created "2020-06-05" @default.
• W3029763038 creator A5003826371 @default.
• W3029763038 creator A5012380163 @default.
• W3029763038 creator A5020914791 @default.
• W3029763038 creator A5021498685 @default.
• W3029763038 creator A5028021994 @default.
• W3029763038 creator A5058368410 @default.
• W3029763038 creator A5067726122 @default.
• W3029763038 creator A5087366284 @default.
• W3029763038 date "2020-05-20" @default.
• W3029763038 modified "2023-09-27" @default.
• W3029763038 title "Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer." @default.
• W3029763038 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e21503" @default.
• W3029763038 hasPublicationYear "2020" @default.
• W3029763038 type Work @default.
• W3029763038 sameAs 3029763038 @default.
• W3029763038 citedByCount "0" @default.
• W3029763038 crossrefType "journal-article" @default.
• W3029763038 hasAuthorship W3029763038A5003826371 @default.
• W3029763038 hasAuthorship W3029763038A5012380163 @default.
• W3029763038 hasAuthorship W3029763038A5020914791 @default.
• W3029763038 hasAuthorship W3029763038A5021498685 @default.
• W3029763038 hasAuthorship W3029763038A5028021994 @default.
• W3029763038 hasAuthorship W3029763038A5058368410 @default.
• W3029763038 hasAuthorship W3029763038A5067726122 @default.
• W3029763038 hasAuthorship W3029763038A5087366284 @default.
• W3029763038 hasConcept C121608353 @default.
• W3029763038 hasConcept C126322002 @default.
• W3029763038 hasConcept C143998085 @default.
• W3029763038 hasConcept C167135981 @default.
• W3029763038 hasConcept C2776256026 @default.
• W3029763038 hasConcept C2778715236 @default.
• W3029763038 hasConcept C50382708 @default.
• W3029763038 hasConcept C71924100 @default.
• W3029763038 hasConcept C72563966 @default.
• W3029763038 hasConcept C90924648 @default.
• W3029763038 hasConceptScore W3029763038C121608353 @default.
• W3029763038 hasConceptScore W3029763038C126322002 @default.
• W3029763038 hasConceptScore W3029763038C143998085 @default.
• W3029763038 hasConceptScore W3029763038C167135981 @default.
• W3029763038 hasConceptScore W3029763038C2776256026 @default.
• W3029763038 hasConceptScore W3029763038C2778715236 @default.
• W3029763038 hasConceptScore W3029763038C50382708 @default.
• W3029763038 hasConceptScore W3029763038C71924100 @default.
• W3029763038 hasConceptScore W3029763038C72563966 @default.
• W3029763038 hasConceptScore W3029763038C90924648 @default.
• W3029763038 hasFunder F4320332161 @default.
• W3029763038 hasLocation W30297630381 @default.
• W3029763038 hasOpenAccess W3029763038 @default.
• W3029763038 hasPrimaryLocation W30297630381 @default.
• W3029763038 hasRelatedWork W12336852 @default.
• W3029763038 hasRelatedWork W15508361 @default.
• W3029763038 hasRelatedWork W1671086 @default.
• W3029763038 hasRelatedWork W17183283 @default.
• W3029763038 hasRelatedWork W17235185 @default.
• W3029763038 hasRelatedWork W20396015 @default.
• W3029763038 hasRelatedWork W3586763 @default.
• W3029763038 hasRelatedWork W5151266 @default.
• W3029763038 hasRelatedWork W6870675 @default.
• W3029763038 hasRelatedWork W7982398 @default.
• W3029763038 isParatext "false" @default.
• W3029763038 isRetracted "false" @default.
• W3029763038 magId "3029763038" @default.
• W3029763038 workType "article" @default.